Exova adds 3-years to GSK environmental monitoring contract

By Staff Reporter

- Last updated on GMT

Image: iStock/philhol
Image: iStock/philhol

Related tags: United kingdom, Glaxosmithkline

GSK has renewed an environmental monitoring contract with Exova across manufacturing sites in the UK and Ireland.

GlaxoSmithKline has been using testing, calibrating and advising company Exova since 2009, and a contract renewal will see the firms work together for at least another three years across eight of the Big Pharma’s production sites in the UK and Ireland.

Exova will continue to provide GSK with health and safety and environmental performance services, working both from the manufacturing sites and at its environmental laboratories.

Alastair Wolff, sector director of Infrastructure & Environment at Exova, said his firm was “delighted to continue this partnership,”​ adding the renewal of the contract until 2019 is “testament to the strong relationships we build with our customers and the quality of our technically demanding testing services.”

GSK’s environmental health and safety manager Dave Postle added: “We have developed a strong relationship with Exova who have delivered an effective, competent and compliant service for GSK over a number of years in these specialised areas.

“We look forward to continuing and developing this over the next three years.”

GSK’s UK and Ireland network includes sites in Ware, Hertfordshire​, Barnard Castle, County Durham, and Montrose, Scotland which are all part of a £275m ($331m) expansion project announced by the company last July​.

Related news

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Related suppliers

Follow us


View more